<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04715269</url>
  </required_header>
  <id_info>
    <org_study_id>SZMC/IRB/0022</org_study_id>
    <nct_id>NCT04715269</nct_id>
  </id_info>
  <brief_title>Role of Alprazolam in the Management of Acute Coronary Syndrome</brief_title>
  <acronym>A-ACS-PK</acronym>
  <official_title>Effect of Alprazolam on Heart Rate and Acute Inflammatory Marker in Acute Coronary Syndrome Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohaib Ashraf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheikh Zayed Federal Postgraduate Medical Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiovascular disease has always been one of the most concerning ailments of all times&#xD;
      considering mortality. On one end due to the emergence of pharmaceutical technology, there is&#xD;
      a reduction in mortality, on the other hand owing to a sedentary lifestyle the incidence of&#xD;
      this disease is increasing. Hence leading to up slopping trend in cardiovascular prevalence.&#xD;
      Acute coronary syndrome is one of the most deadly and acute presentations of cardiology&#xD;
      requiring immediate intervention to dampen the frequency of complications. One of the&#xD;
      fundamental goals in the treatment of ACS is to lower the heart rate so that load on&#xD;
      myocardial tissue can be reduced. In order to do so, we already have multiple options like&#xD;
      beta-blockers, calcium channel blockers, and new generation ivabradine (not affecting blood&#xD;
      pressure unlike others).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      World has studied the increased prevalence of anxiety as a concomitant factor in ACS patients&#xD;
      causing detrimental effects on cardiovascular outcomes being anxiety as one of the first&#xD;
      responses to chest pain and hospital admission causing tachycardia. This study is designed to&#xD;
      achieve the goals of lowering the heart using the anxiolytic property of alprazolam. This&#xD;
      randomized, parallel group, close label, placebo-controlled, event driven, interventional&#xD;
      clinical superiority study will be conducted in Cardiology department of Shaikh Zayed&#xD;
      Hospital with a sample size of 48 allocating using lottery method in both experimental and&#xD;
      control group. Heart Rate at baseline and after 6 hours will be monitored in both groups to&#xD;
      establish the fall of heart rate in both patients. Data will be collected by using&#xD;
      pre-designed performa and will be entered and analyzed via SAS 9.4. Statistical analysis will&#xD;
      be done using T-test and p value &lt;0.05 will be considered significant.&#xD;
&#xD;
      Significance of the study is to lower the required dosage of beta-blockers in order to&#xD;
      achieve optimum beta-blockade using an anxiolytic while not affecting the blood pressure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 25, 2020</start_date>
  <completion_date type="Anticipated">February 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This randomized, close label, placebo-controlled study with superiority framework as add-on therapy in ACS patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Masking will be done for all participants</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>upto 72 hours</time_frame>
    <description>Heart Rate reduction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Hospital stay</measure>
    <time_frame>upto 14 days</time_frame>
    <description>Number of days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>upto 14 days</time_frame>
    <description>death of patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>recurrent symptomatic ischemia</measure>
    <time_frame>72 hours</time_frame>
    <description>episodes of angina</description>
  </primary_outcome>
  <primary_outcome>
    <measure>erythrocyte sedimentation rate (ESR)</measure>
    <time_frame>upto 72 hours</time_frame>
    <description>Acute phase reactants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>upto 72 hours</time_frame>
    <description>Acute phase reactants</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Myocardial Infarction</condition>
  <condition>ST Elevation Myocardial Infarction</condition>
  <condition>Heart Diseases</condition>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>Alprazolam Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5mg Alprazolam will be given to the patient at the time of presentation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The empty capsule will be given to the patient at the time of presentation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprazolam</intervention_name>
    <description>Alprazolam 0.5 mg will be given when the patient with acute coronary syndrome would present to the emergency</description>
    <arm_group_label>Alprazolam Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Empty capsule</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Systolic BP&gt;100mm Hg Age between 18-80 years Sinus Rhythm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiogenic Shock / Hypotension&#xD;
&#xD;
          -  Known Asthma/COPD&#xD;
&#xD;
          -  Bradycardia (HR &lt; 60)&#xD;
&#xD;
          -  Already on Beta blockers/ Anxiolytics&#xD;
&#xD;
          -  Sick sinus syndrome&#xD;
&#xD;
          -  Second or third-degree heart block (in the absence of pacemaker)&#xD;
&#xD;
          -  Decompensated heart failure&#xD;
&#xD;
          -  With documented hypersensitivity to the drug or components&#xD;
&#xD;
          -  Valvular Heart Diseases&#xD;
&#xD;
          -  Congenital Heart Diseases&#xD;
&#xD;
          -  Status post CABG&#xD;
&#xD;
          -  Any co-morbidities except Diabetes Mellitus and Hypertension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qazi Abdul Saboor, MBBS</last_name>
    <role>Study Chair</role>
    <affiliation>Shaikh Zayed Post-Graduate Medical Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sohaib Ashraf, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaikh Zayed Post-Graduate Medical Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sohaib Ashraf, MBBS</last_name>
    <phone>+18573167995</phone>
    <email>sohaib@skzmdc.edu.pk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmad Imran, MBBS</last_name>
    <phone>+923334474523</phone>
    <email>ahmad.imran@skzmdc.edu.pk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shaikh Zayed Post-Graduate Medical Institute</name>
      <address>
        <city>Lahore</city>
        <zip>54600</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qazi Abdul Saboor, MBBS</last_name>
      <phone>+923004127598</phone>
      <email>drsaboor04@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Sohaib Ashraf, MBBS</last_name>
      <phone>8573167995</phone>
      <email>sohaib-ashraf@outlook.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sohaib Ashraf, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Usama Farooq, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ayesha Khaqan, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abubakar Hilal, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arz Muhammad, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sheikh Zayed Federal Postgraduate Medical Institute</investigator_affiliation>
    <investigator_full_name>Sohaib Ashraf</investigator_full_name>
    <investigator_title>Registrar Cardiology</investigator_title>
  </responsible_party>
  <keyword>Cardiology</keyword>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Heart Rate</keyword>
  <keyword>Alprazolam</keyword>
  <keyword>Anxiolytic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

